Other languages BioVie Inc.

Equities

BIVI

US09074F2074

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-30 EDT			5-day change	1st Jan Change
0.49 ^USD	-1.01%		-0.37%	-61.11%

04-29	BioVie Gets up to $13.1 Million From US Defense Department to Evaluate Bezisterim for Long COVID	MT
04-29	BioVie Awards up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim for the Treatment of Long COVID	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioVie Gets up to $13.1 Million From US Defense Department to Evaluate Bezisterim for Long COVID	04-29
BioVie Awards up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim for the Treatment of Long COVID	04-29
BioVie Inc. Announces Pipeline Update and Near-Term Clinical Priorities	03-11
Top Midday Decliners	03-04
BioVie Prices $21 Million Offering of Shares, Warrants; Stock Slumps	03-04
BioVie Prices $21 Million Public Offering of Common Stock, Warrants	03-04
Sector Update: Health Care Stocks Rising Late Afternoon	03-01
Top Midday Gainers	03-01
Sector Update: Health Care Stocks Advance Friday Afternoon	03-01
BioVie Shares Rise as Alzheimer's, Parkinson's Drug Trials Show Potential Improvements	03-01
BioVie Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-13
BioVie Says Modified Phase 3 Trial for Alzheimer's Disease Treatment Missed Statistical Significance Amid Protocol Errors	11-29
BioVie Inc. Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer?s Disease	11-29
BioVie Reports 'Positive' Phase 2b Trial Data of BIV201 in Refractory Ascites	11-13
BioVie Inc. Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease - The Liver Meeting® 2023	11-13
BioVie Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-08
BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company's Ascites Phase 2 Trial Accepted for Presentation at AASLD - The Liver Meeting®? 2023	23-10-26
BioVie Shares Rise After Completion of Last Patient Treatment Visit in Trial for Mild to Moderate Alzheimer's Disease	23-09-26
BioVie Inc. Presents Data for NE3107 At 2023 International Congress of Parkinson?s Disease and Movement Disorders	23-08-28
BioVie Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BioVie Inc.

Equities

BIVI

US09074F2074

Other languages

Filters